Oct 11 (Reuters) - Pfizer Inc said a late-stage trial of its experimental pain drug showed the drug's long-term safety profile was comparable to those of other similar formulations.
The trial was testing the safety of the drug, called ALO-02, when administered for up to 12 months.
The drug uses a technology that discourages common methods of drug abuse associated with prescription opioid use.
(Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)
((esha.dey@thomsonreuters.com)(within U.S. +1 646 223 8780, outside U.S. +91 80 4135 5800)(Reuters Messaging: esha.dey.thomsonreuters.com@reuters.net))
Keywords: PFIZER TRIAL PAINDRUG/